2. Immunology/Inflammation
  3. Interleukin Related
  4. Ustekinumab

Ustekinumab  (Synonyms: CNTO-1275; L04AC05; TT-20)

製品番号: HY-P9909 純度: 99.83%
COA Technical Support

Ustekinumab is an anti-IL-12/IL-23 IgG1κ human monoclonal antibody.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号 : 815610-63-0

容量 価格（税別） 在庫状況 数量
1 mg $550 在庫あり
5 mg $970 在庫あり
10 mg $1550 在庫あり
25 mg $2950 在庫あり
50 mg   お問い合わせ  
100 mg   お問い合わせ  

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 4 publication(s) in Google Scholar

Ustekinumab Featured Recommendations:

Ustekinumab 関連抗体

Top Publications Citing Use of Products

    Ustekinumab purchased from MedChemExpress. Usage Cited in: Adv Mater. 2024 Dec 6:e2412429.  [Abstract]

    Cascade repair probiotic gene editing system improves DSS-induced UC compared with clinical drugs. Daily change in body weight for each group, including Health, Control, 5-ASA (5-Aminosalicylic acid; 40 mg/kg; oral), vedolizumab (5 mg/kg; iv), ustekinumab (5 mg/kg; iv), infliximab (5 mg/kg; iv), and LGG-M@P, over 10 days. The above drugs were administered once every two days. Measurements of colonic tissue length in various groups on day 10. DAI changes throughout 10 days, calculated as the total of the stool consistency (0–3), fecal bleeding (0–4), and weight loss (0–4) indexes.

    Ustekinumab purchased from MedChemExpress. Usage Cited in: Adv Mater. 2024 Dec 6:e2412429.  [Abstract]

    Cascade repair probiotic gene editing system improves DSS-induced UC compared with clinical drugs. The groups are: Health, Control, 5-ASA (5-Aminosalicylic acid; 40 mg/kg; oral), vedolizumab (5 mg/kg; iv), ustekinumab (5 mg/kg; iv), infliximab (5 mg/kg; iv), and LGG-M@P, over 10 days. The above drugs were administered once every two days. Mice colonic sections stained with HE on day 10 following the indicated treatments.

    Ustekinumab purchased from MedChemExpress. Usage Cited in: Adv Mater. 2024 Dec 6:e2412429.  [Abstract]

    Cascade repair probiotic gene editing system improves DSS-induced UC compared with clinical drugs. The groups are: Health, Control, 5-ASA (5-Aminosalicylic acid; 40 mg/kg; oral), vedolizumab (5 mg/kg; iv), ustekinumab (5 mg/kg; iv), infliximab (5 mg/kg; iv), and LGG-M@P, over 10 days. The above drugs were administered once every two days. Colonic MPO levels on day 10.) Colonic TNF-α, IL-6, and IL-1β levels on day 10.

    Ustekinumab purchased from MedChemExpress. Usage Cited in: Nat Immunol. 2021 Sep;22(9):1107-1117.  [Abstract]

    Flow cytometry quantification of cell viability and lipid ROS of HC neutrophils cultured in vitro with 20% SLE serum supplemented with anti-CXCL11 (0.1, 1, 5 µg/ml) or Ustekinumab (0.1, 1, 10 µg/ml) for 16 hours.

    Interleukin Related アイソフォーム固有の製品をすべて表示:

    すべてのアイソフォームを表示
    IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22 IL-18

    • 生物活性

    • プロトコル

    • 純度とドキュメンテーション

    • 参考文献

    • カスタマーレビュー

    製品説明

    Ustekinumab is an anti-IL-12/IL-23 IgG1κ human monoclonal antibody.

    Isotype

    Human IgG1 kappa
    Recommend Isotype Controls
    Species Reactivity

    Human
    IC50 & Target

    IL-12

     

    IL-23

     

    体外実験

    Ustekinumab is a human monoclonal antibody that prevents human IL-12 and IL-23 from binding to the IL-12Rβ1 receptor chain of IL-12 (IL-12Rβ1/β2) and IL-23 (IL-12Rβ1/23R) receptor complexes on the surface of natural killer cells and T-cells[1]. Ustekinumab is a human IgG1 kappa (κ) monoclonal antibody against the IL-12/IL-23 p40 subunit that prevents its interaction with IL-12Rβ1, thereby blocking subsequent signaling. The FcRn affinities at pH 6.0 fell in a narrow range for all 11 antibodies. The equilibrium dissociation constant (KD) is calculated relative to Ustekinumab (Ustekinumab=1.0)[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Ustekinumab 関連抗体
    臨床実験
    Gene ID

    3593  [NCBI]

    Accession
    Application

    ELISA, FACS, Functional assay
    Conjugated

    Unconjugated
    Reconsititution

    The product can be reconstituted/diluted with sterile PBS or saline.
    分子量

    145.63 kDa

    CAS 番号
    Appearance

    Liquid

    Color

    Colorless to light yellow

    SMILES

    [Ustekinumab]
    輸送条件

    Shipping with dry ice.
    Formulation

    Please refer to the lot-specific COA for specific buffer information.
    保管条件

    Please store the product under the recommended conditions in the Certificate of Analysis.
    Format
    • Human IgG1 kappa
    Biological Activity
    • Immobilized IL-12 beta Protein, Human (HEK293, Fc, HY-P73160) can bind Ustekinumab. The EC50 for this effect is 13.6 ng/mL.
    • Flow cytometric analysis of 1×106 Jurkat cells labelling IL-12B (red) with Ustekinumab (HY-P9909). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa Isotype Control (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
    純度とドキュメンテーション

    純度: 99.83%

    COA (232 KB) SDS-PAGE (109 KB) SEC-HPLC (86 KB)

    Inhibitory Antibodies User Guide (603 KB)
    参考文献
    細胞実験
    [2]

    HUVECs are grown on calibrated glass coverslips to a confluency of 80%. Subsequently, cells are incubated with 200 µg/mL Ustekinumab AlexaFluor488 and Briakinumab AlexaFluor594 for 20 min at 37°C, pH 7.3, washed three times, and chased in fresh medium for an additional 20 min before fixation. Antibodies are directly labeled. FcRn binding is quality controlled by SPR analysis. Cells are then counterstained with anti-FcRn monoclonal antibody DVN22, followed by anti-mouse secondary antibodies conjugated to AlexaFluor647. Imaging is performed on a Leica SP8 confocal microscope[2].

    MedChemExpress (MCE) はこれらの方法の精度を確認していません。 こちらは参照専用です。
    参考文献
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Ustekinumab Related Classifications

    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    質量   濃度   体積   分子量 *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    一般には略語で表示されます：C1V1 = C2V2

    濃度 （開始） × 体積 （開始） = 濃度 （終了） × 体積 （終了）
    × = ×
    C1   V1   C2   V2
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Ustekinumab815610-63-0CNTO-1275 L04AC05 TT-20CNTO1275CNTO 1275TT20TT 20TT-20Interleukin RelatedILInhibitorinhibitorinhibit

    最近チェックした製品:

    オンラインお問い合わせ

    Your information is safe with us. * Required Fields.

    製品名

    		  

    カスタマ需要量 *

    お名前 *

    		 

    タイトル

    メールアドレス *

    		 

    電話番号 *

    デパートメント

    		 

    組纖名 *

    市区町村

    都道府県

    国或いは地域 *

    		      

    必ず会社名を記載ください。個人への返信は行いません。

    備考

    バルクお問い合わせ

    Inquiry Information

    製品名:
    Ustekinumab
    製品番号:
    HY-P9909
    数量:
    MCE 日本正規代理店:

    カスタマーレビュー

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    製品名

    		  

    Lot #

    お名前 *

    		 

    メールアドレス *

    電話番号 *

    		 

    部門 *

    組纖名 *

    		 

    国或いは地域 *

    備考

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.